Mary Lane
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,787 of the $7,793 with a category attached, or 74.3%. It is spread thinly across 21 manufacturers, the largest accounting for just 20.3%. Reporting peaked in 2024 at $3,700 and has fallen 54.9% since, to $1,670 in 2025. Among family clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $112.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- GSK$1K
- Johnson & Johnson$1K
- Fresenius Kabi USA, LLC$582
- Astellas Pharma US Inc$422
- AbbVie$320
- plus $2K from 15 others
What the payments were for
- Consulting fees$1,72822%
- Food & beverage$5,78774%
- Education$2794%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 15 | $1,584 |
| GSK | 4 | $1,410 |
| Johnson & Johnson | 13 | $1,301 |
| Fresenius Kabi USA, LLC | 2 | $582 |
| Astellas Pharma US Inc | 4 | $422 |
| AbbVie | 6 | $320 |
| Eisai Inc. | 3 | $309 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $254 |
| Merck | 2 | $220 |
| Regeneron Healthcare Solutions, Inc. | 2 | $175 |
| Adaptive Biotechnologies Corporation | 1 | $163 |
| Beone Medicines USA, Inc. | 1 | $133 |
| Agios Pharmaceuticals, Inc. | 1 | $122 |
| Alnylam Pharmaceuticals Inc. | 1 | $121 |
| Gilead | 2 | $120 |
| Pfizer | 1 | $115 |
| Beigene USA, Inc. | 4 | $114 |
| AVEO Pharmaceuticals, Inc. | 1 | $113 |
| Daiichi Sankyo Inc. | 1 | $84 |
| Stemline Therapeutics Inc. | 1 | $83 |
| Incyte Corporation | 1 | $49 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,793 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 11 | $2,224 |
| Letrozole | 38 | $1,033 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 27 | $727 |
| Anastrozole | 32 | $582 |
| Oxycodone Hcl | 23 | $498 |
| Prochlorperazine Maleate | 21 | $325 |
| Alendronate Sodium | 15 | $241 |
| Hydroxyurea | 15 | $240 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 15 | $225 |
| Potassium Chloride | 22 | $215 |
| Ondansetron OdtOndansetron | 11 | $188 |
| Ondansetron Hcl | 21 | $182 |
| Dexamethasone | 23 | $173 |
| Famotidine | 11 | $157 |
| Levothyroxine Sodium | 13 | $104 |
Paid to pharmacies, not to this prescriber.
Other family in Lacey
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
- Kaitlin BrasierSeattle$29K
- Karen JohnsonSeattle$16K
- Brittanee WorthySpokane Valley$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.